0000899243-22-016336.txt : 20220503 0000899243-22-016336.hdr.sgml : 20220503 20220503164733 ACCESSION NUMBER: 0000899243-22-016336 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220501 FILED AS OF DATE: 20220503 DATE AS OF CHANGE: 20220503 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MCGLYNN MARGARET G CENTRAL INDEX KEY: 0001215126 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 22887832 MAIL ADDRESS: STREET 1: C/O MERCK & CO INC STREET 2: ONE MERCK DRIVE PO BOX 100 CITY: WHITEHOUSE STATION STATE: NJ ZIP: 08889-0100 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-05-01 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001215126 MCGLYNN MARGARET G C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 1 0 0 0 Common Stock 2022-05-01 4 D 0 921 D 178 D Deferred Stock Units 2022-05-01 4 A 0 921 A Common Stock 921 5609 D Stock Option (Right to Buy) 276.17 2022-05-01 4 A 0 4462 0.00 A 2022-05-01 2032-04-30 Common Stock 4462 4462 D Upon the vesting of restricted stock units granted to Ms. McGlynn on May 1, 2021, Ms. McGlynn deferred the receipt of 921 shares of common stock and received instead 921 deferred stock units pursuant to the Issuer's deferred compensation plan. As a result, Ms. McGlynn is reporting the disposition of 921 shares of common stock in exchange for an equal number of deferred stock units. Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McGlynn's service on the Issuer's board of directors, (ii) a change of control of the Issuer and (iii) Ms. McGlynn's disability or death. /s/ Sabrina Yohai, Attorney-in-Fact 2022-05-03